2025 Scientific Sessions

Lunch Program: Emerging Microvascular Technologies to Improve STEMI Outcomes

Despite advances in reperfusion with primary stenting, STEMI outcomes have stagnated over the past 20 years, with 1 in 5 patients developing heart failure at 1 year.  Hear global thought leaders discuss the rationale and science behind STEMI outcomes and what needs to be done to improve them.   Learn about SSO2 Therapy and how it reduces infarct size in STEMI patients and hear about experiences with the therapy.
The State of STEMI: Past, Present, Future Therapeutic Solutions
Gregg W. Stone, M.D., Icahn School of Medicine at Mount Sinai, New York, NY
Microcirculation is Myocardium: You Only Got One Shot
Sandeep Nathan, M.D., FSCAI, The University of Chicago, Chicago, IL
The Urgent Call for Highly Cost-Effective Therapies for STEMI
David J. Cohen, M.D., FSCAI, St. Francis Hospital, New York, NY
Investigative Approach vs. Standard of Care: Left Ventricular Unloading
Michael J. Lim, M.D., FSCAI, Poplar Bluff Regional Medical Center, Poplar Bluff, MO
Fireside Chat / Panel Discussion
Timothy D. Henry, M.D., MSCAI, The Christ Hospital Health Network, Dayton, KY, Srihari S. Naidu, MD, FSCAI, Westchester Medical Center, New York, NY and Megha Prasad, M.D., NewYork-Presbyterian Columbia University Irving Medical Center, new york city, NY